AEMD - Aethlon Medical, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.4000
-0.1800 (-6.98%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close2.5800
Open2.5800
Bid2.4000 x 1800
Ask2.3900 x 900
Day's Range2.1701 - 2.5900
52 Week Range0.7600 - 21.3000
Volume1,978,004
Avg. Volume976,398
Market Cap16.708M
Beta (5Y Monthly)0.24
PE Ratio (TTM)N/A
EPS (TTM)-5.8800
Earnings DateFeb 09, 2020 - Feb 13, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
  • Benzinga

    13 Coronavirus-Related Stocks To Watch Amid Wuhan Outbreak

    Airlines, hotels, casinos and stocks linked to Wuhan, China, continue to fall as fear of the coronavirus deters international travel and all but halts activity in the virus epicenter. Alpha Pro Tech, Ltd. (NYSE: APT) manufactures masks and protective apparel — goods already in high demand in China. Lakeland Industries, Inc. (NASDAQ: LAKE) also produces protective clothes for high-risk workers, such as the medical professionals and public health officials exposing themselves to patients.

  • The Zacks Analyst Blog Highlights: Novavax, NanoViricides, Aethlon Medical and Oncolytics Biotech
    Zacks

    The Zacks Analyst Blog Highlights: Novavax, NanoViricides, Aethlon Medical and Oncolytics Biotech

    The Zacks Analyst Blog Highlights: Novavax, NanoViricides, Aethlon Medical and Oncolytics Biotech

  • Health stocks reverse coronavirus gains as one analyst says the market is overreacting
    Yahoo Finance

    Health stocks reverse coronavirus gains as one analyst says the market is overreacting

    Virus originating in Wuhan, China affected stock markets Tuesday, but one analyst said reactions were too strong.

  • PR Newswire

    Aethlon Medical Announces Completion of $3.77 Million Registered Direct Offering

    Aethlon Medical, Inc. (Nasdaq:AEMD) ("Aethlon" or the "Company"), a medical device technology company focused on developing products to diagnose and treat life and organ threatening diseases, today announced the completion of its previously announced registered direct offering of 1,885,378 shares of its common stock, at a purchase price per share of $2.00, priced at-the-market under Nasdaq rules. Additionally, Aethlon issued to the purchasers unregistered warrants to purchase up to 942,689 shares of common stock. The warrants have an exercise price of $2.75 per share of common stock, are exercisable immediately and will expire five and one-half years from the issuance date.

  • Coronavirus Infects Wall Street: Stocks to Gain & Lose
    Zacks

    Coronavirus Infects Wall Street: Stocks to Gain & Lose

    While travel-related stocks were hit hard on concerns over coronavirus, experimental vaccine companies rallied.

  • Experimental vaccine stocks jump on concerns about new virus in China
    MarketWatch

    Experimental vaccine stocks jump on concerns about new virus in China

    Shares of small vaccine makers gained in trading on Tuesday morning over growing concerns about the spread of a new coronavirus in China that has infected at least 200 people.

  • PR Newswire

    Aethlon Medical Announces $3.77 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

    Aethlon Medical, Inc. (Nasdaq:AEMD) (the "Company"), a medical device technology company focused on developing products to diagnose and treat life and organ threatening diseases, today announced that it has entered into definitive agreements with certain institutional investors for the purchase in a registered direct offering of 1,885,378 shares of its common stock, at a purchase price per share of $2.00, priced at-the-market under Nasdaq rules. Additionally, Aethlon has agreed to issue to the investors unregistered warrants to purchase up to 942,689 shares of common stock. The warrants have an exercise price of $2.75 per share of common stock, will be exercisable immediately and will expire five and one-half years from the issuance date.

  • PR Newswire

    Aethlon Medical Announces Closing of $5 Million Public Offering

    Aethlon Medical, Inc. (Nasdaq: AEMD) (the "Company"), a medical device technology company focused on developing products to diagnose and treat life and organ threatening diseases, today announced the closing of the previously announced underwritten public offering of 3,333,334 shares of common stock (which includes pre-funded warrants to purchase shares of common stock in lieu thereof), and common warrants to purchase up to an aggregate of 3,333,334 shares of common stock at a public offering price of $1.50 per share. Each share of common stock (or pre-funded warrant in lieu thereof) was sold together with a common warrant to purchase one share of common stock. The common warrants have an exercise price of $1.50 per share, are immediately exercisable, and will expire five years from the date of issuance. The Company has also granted the underwriter a 45-day option to purchase up to an additional 499,999 shares of common stock and/or common warrants to purchase up to 499,999 shares of common stock, at the public offering price, less underwriting discounts and commission.

  • PR Newswire

    Aethlon Medical Announces Pricing of $5 Million Public Offering

    Aethlon Medical, Inc. (Nasdaq:AEMD) (the "Company"), a medical device technology company focused on developing products to diagnose and treat life and organ threatening diseases, today announced the pricing of an underwritten public offering of 3,333,334 shares of common stock (which includes pre-funded warrants to purchase shares of common stock in lieu thereof), and common warrants to purchase up to an aggregate of 3,333,334 shares of common stock at a public offering price of $1.50 per share. Each share of common stock (or pre-funded warrant in lieu thereof) is being sold together with a common warrant to purchase one share of common stock. The common warrants have an exercise price of $1.50 per share, are immediately exercisable, and will expire five years from the date of issuance. The Company has granted the underwriter a 45-day option to purchase up to an additional 499,999 shares of common stock and/or common warrants to purchase up to 499,999 shares of common stock, at the public offering price, less underwriting discounts and commission.

  • Here's Why We Worry About Aethlon Medical's (NASDAQ:AEMD) Cash Burn Situation
    Simply Wall St.

    Here's Why We Worry About Aethlon Medical's (NASDAQ:AEMD) Cash Burn Situation

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

  • PR Newswire

    Aethlon Medical Announces Second Quarter Financial Results and Provides Corporate Update

    SAN DIEGO , Nov. 1, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on developing products to diagnose and treat life and organ threatening diseases, ...

  • PR Newswire

    Aethlon Medical To Release Second Quarter Financial Results and Host Conference Call on November 1, 2019

    SAN DIEGO, Oct. 29, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a medical device technology company focused on unmet needs in global health, today announced that it will issue financial results for its second quarter fiscal year 2020, ended September 30, 2019, at 4:15pm Eastern time on Friday, November 1, 2019. Management will host a conference call on Friday, November 1, 2019 at 4:30pm Eastern time to review financial results and recent corporate developments. To listen to the call by phone, interested parties within the U.S. should call 1-844-836-8741 and International callers should call 1-412-317-5442.

  • AEMD: IDE Approved. Hemopurifier U.S. Clinical Cancer Program On-Deck…
    Zacks Small Cap Research

    AEMD: IDE Approved. Hemopurifier U.S. Clinical Cancer Program On-Deck…

    By Brian Marckx, CFA NASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT When Aethlon Medical (NASDAQ:AEMD) reported fiscal Q1 2020 financial results in August, management noted that they anticipated imminent filing of an Investigational Device Exemption (IDE) seeking approval to initiate U.S.-based clinical studies for their Hemopurifier device in cancer patients. Not only did that filing

  • PR Newswire

    Aethlon Announces Reverse Stock Split

    SAN DIEGO, Oct. 14, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD) ("Aethlon" or the "Company"), a therapeutic medical device and technology company focused on unmet needs in global health, announced today that at the annual meeting of stockholders of the Company, held October 14, 2019, its stockholders voted to approve a proposal authorizing the Board of Directors of the Company to effect a reverse stock split of Aethlon's outstanding common stock. Following the special meeting of stockholders, the Board of Directors approved a 1-for-15 reverse stock split.

  • PR Newswire

    Aethlon Medical Announces FDA Approval Of IDE For Oncology Indications

    SAN DIEGO, Oct. 7, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic medical device and technology company focused on unmet needs in global health, announced today that the FDA has approved its Investigational Device Exemption (IDE) application to initiate an Early Feasibility Study (EFS) of the Company's proprietary Hemopurifier® in patients with head and neck cancer in combination with standard of care pembrolizumab (Keytruda).

  • PR Newswire

    Aethlon Medical Receives Extension from Nasdaq to Regain Compliance with Continued Listing Requirements

    SAN DIEGO, Oct. 3, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic technology company focused on unmet needs in global health, announced today that on October 2, 2019, Nasdaq granted Aethlon Medical an extension of time to regain compliance with the exchange's continued listing requirement of a minimum $2.5 million of stockholders' equity. This extension is conditional upon Aethlon Medical completing a reverse stock split and trading at or above Nasdaq's minimum $1.00 bid price requirement for a period of ten consecutive trading days on or before October 29, 2019. The Company is requesting stockholder approval of the reverse stock split at its Annual Meeting of Stockholders to be held on October 14, 2019 in order to meet this requirement.

  • How Much Of Aethlon Medical, Inc. (NASDAQ:AEMD) Do Insiders Own?
    Simply Wall St.

    How Much Of Aethlon Medical, Inc. (NASDAQ:AEMD) Do Insiders Own?

    If you want to know who really controls Aethlon Medical, Inc. (NASDAQ:AEMD), then you'll have to look at the makeup of...

  • Market Exclusive

    Market Morning: Prorogation Ruled Rogue, High Demand for Fed Repo, New Breast Cancer Tests

    British High Court Rules Against Johnson Parliament Prorogation Apparently, proroguing Parliament was not Boris Johnson’s prerogative. The British high court ruled today that the Prime Minister acted unlawfully in suspending Parliament until October 14th, and that he misled the Queen in advising that Parliament should be suspended. Johnson is now facing calls to resign, which […]The post Market Morning: Prorogation Ruled Rogue, High Demand for Fed Repo, New Breast Cancer Tests appeared first on Market Exclusive.

  • Aethlon Announces Collaboration to Identify Exosomes Involved in Cancer Progression and Treatment Resistance
    PR Newswire

    Aethlon Announces Collaboration to Identify Exosomes Involved in Cancer Progression and Treatment Resistance

    SAN DIEGO, Sept. 24, 2019 /PRNewswire/ -- EXOSOME SCIENCES, a subsidiary of Aethlon Medical, Inc. (AEMD), announced a research collaboration to identify and characterize exosomes derived from patients with solid tumors such as pancreas cancer, as well as from families with genetically high risk of developing cancer.  These cancer-derived exosomes may serve as early markers for cancer diagnostics, cancer progression and treatment resistance. Exosome Sciences, Inc., a majority owned subsidiary of Aethlon Medical, Inc., is a diagnostic company focused on the discovery of exosomal biomarkers to diagnose and monitor cancer and neurological disease progression.

  • PR Newswire

    Aethlon Medical Receives National Cancer Institute Contract Award

    SAN DIEGO, Sept. 16, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic technology company focused on unmet needs in global health, announced today that the National Cancer Institute (NCI) has awarded the Company an SBIR Phase 2 contract for Topic 359, a solicitation entitled "Technologies for Differential Isolation of Exosomes and Oncosomes." This solicitation prioritized the advancement of technologies for isolating exosomes from biofluids for applications in oncology research and clinical care. Exosomes are nanoparticles that are abundantly released from cancer cells and carry the complement of a tumor's genetic and protein cargo, making them important targets for non-invasive liquid biopsies in cancer. Aethlon is actively developing assays in this area through its majority-owned subsidiary, Exosome Sciences, Inc. However, there remains a need for high-throughput and selective technologies which isolate exosomes from various bodily fluids that could be adopted in clinical workflows.

  • PR Newswire

    Aethlon Medical Announces First Quarter Financial Results and Provides Corporate Update

    SAN DIEGO , Aug. 14, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health, today reported financial results for its first ...

  • PR Newswire

    Aethlon Medical To Release First Quarter Financial Results and Host Conference Call on August 14, 2019

    SAN DIEGO, Aug. 7, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic technology company focused on unmet needs in global health, today announced that it will issue financial results for its first quarter fiscal year 2020, ended June 30, 2019, at 4:15pm Eastern time on Wednesday, August 14, 2019. Management will host a conference call on Wednesday, August 14, 2019 at 4:30pm eastern time to review financial results and recent corporate developments. To listen to the call by phone, interested parties within the U.S. should call 1-844-836-8741 and International callers should call 1-412-317-5442.

  • Zacks Small Cap Research

    AEMD: SeaStar Collaboration Is Intriguing, More Evidence of Exosomes’ Role in Cancer Progression

    Aethlon Medical (AEMD) reported financial results for their fiscal fourth quarter ending March 31, 2019 and provided a business update. Revenue of $80k was recorded in the quarter, representing the initial payment under AEMD’s ongoing NCI grant (The Hemopurifier Device for Targeted Removal of Breast Cancer Exosomes from the Blood Circulation), which was awarded in September 2018 and will pay a total of $298.4k through ~August 2019. This revenue relates to a completed milestone, “to evaluate Hemopurifier-mediated capture of breast cancer exosomes”.

  • PR Newswire

    Aethlon Medical Announces Fiscal Year End Financial Results and Provides Corporate Update

    SAN DIEGO , July 1, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health, today reported financial results for its fiscal ...

  • ACCESSWIRE

    Aethlon Medical, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / July 1, 2019 / Aethlon Medical, Inc. (NASDAQ: AEMD ) will be discussing their earnings results in their 2019 Fourth Quarter Earnings to be held on July 1, 2019 at 4:30 PM Eastern ...